Among the known characteristics in cancerous and neurological diseases at cell and molecule levels are mistakes in the normal process or pathway of the expression of DNA. In addition to published research literatures, preliminary clinical studies indicated that our proprietary drug RP-323 could modulate the mutation of cellular process back to normal differentiation pathways. The specific biochemical process elucidated by RP-323 involves phosphorylation allowing the turning on or off critical DNA expression to produce the necessary enzymes for normal cell proliferation (reproduction of cells), differentiation and/or apoptosis (cell death). For example, RP-323 was able to modulate the synthesis of the mitogen-activated-protein kinase (MAPK) associated with cell proliferation. Therefore, RP-323 was able to ‘repair’ the damaged cellular processes in the abnormal cells back to normal. This reparation is at the molecular level, i.e. DNA transcriptions and protein syntheses of critical enzymes for normal cell functions. To certain cell lines, RP-323 caused cell death. Results of our studies with varieties of cell lines and primary cells indicated RP-323 has a multiple broad spectrum therapeutic functions within the genomic medicine arena.
In addition to the curative therapeutic value, our studies have indicated RP-323 was able to enhance the immune system through cytokine induction with 85-90% efficiency. The strengthening of our body’s immune system is crucial in the treatment of cancerous diseases.
For more information on ‘how it works’ within specific disorders continue to read the neurology, cancer, and hematology pages within this tab.
Click below for the published medical version of ‘how it works’: